1. Introduction {#sec1-pathogens-02-00556}
===============

1.1. The Advent of Culture Independence
---------------------------------------

Culture-independent methods have begun to transition from environmental microbiology, where axenic culture is recognized to yield only 1% of bacteria \[[@B1-pathogens-02-00556]\], to diagnostic microbiology, where culture continues to be a significant element of the accepted standard (Manual of Clinical Microbiology \[[@B2-pathogens-02-00556]\]; itself a very forward-looking text, particularly in [Section 1](#sec1-pathogens-02-00556){ref-type="sec"}, which includes both current practice and commentary on the human microbiome and microbial genomics). In environmental microbiology, the progress of pure culture methods was paralleled by the progress of enrichment cultures \[[@B3-pathogens-02-00556],[@B4-pathogens-02-00556]\], reminding researchers of the presence of uncultured organisms. Continuous efforts to enlarge the realm of the culturable were tedious and trying. Microscopy \[[@B5-pathogens-02-00556]\] and other direct detection methods continued to be used despite significant labor requirements and the difficulties of identifying organisms from morphology and staining alone \[[@B6-pathogens-02-00556]\]. Use of these methods to confirm the quantification of supposedly culturable organisms revealed the "great plate count anomaly" \[[@B7-pathogens-02-00556]\], which suggested that even many organisms thought to be effectively cultured could not, in fact, be accurately detected or quantified in conventional culture.

While environmental microbiology was forced to utilize difficult methods, because so few organisms could be cultured axenically, clinical microbiology continued to develop an admirable efficiency and cost effectiveness. Routine methods were continuously streamlined; such that in 1977, just as rRNA sequencing was entering use in microbial ecology and evolution \[[@B8-pathogens-02-00556]\], only 13 of 38 hospital laboratories were found to include the main culture-independent method, the Gram stain, in microbiological sputum examination \[[@B9-pathogens-02-00556]\]. As published in the Journal of Clinical Microbiology, this led to a confirmation bias; the organisms thought to be most common were indeed found most commonly, and culture biases were reinforced. Further, even as more advanced methods, such as phenotype arrays and whole genome sequencing (WGS; *i.e.*, pathogenomics), were used to characterize isolated strains, the methods were necessarily applied to the cultured isolates.

The advent of nucleic acid ("molecular") methods has opened up the floodgates in environmental microbiology \[[@B10-pathogens-02-00556]\]. Vast microbial diversity, always apparent, has become tangible. Sequencing of diverse ribosomal RNA from communities provides a nearly open ability to identify bacteria and fungi with relative quantification \[[@B11-pathogens-02-00556]\]. Shotgun metagenomic sequencing provides more comprehensive information about identity and function \[[@B12-pathogens-02-00556]\]. Advanced microscopy provides single-cell data about genetics and physiology within populations and communities. Unexpected diversity was uncovered in the form of new and unexpected genera, as well as unexpected diversity within species and phenotypic plasticity within strains. Culture-independent methods have now been brought to bear on human-associated microbial flora (the "human microbiome") in the contexts of apparent health and clinical disease. The results have been well publicized, ("The Gut Microbiota \[Special Issue\]" \[[@B13-pathogens-02-00556]\], for example). The microbial communities required for health are perhaps more diverse than expected and, at the same time, less so than was feared \[[@B14-pathogens-02-00556]\]. The newly available benchmark for this unexplored microbial diversity pushes the scientific community toward greater efforts at bringing uncharacterized organisms into culture and allows an assessment of relative success \[[@B15-pathogens-02-00556],[@B16-pathogens-02-00556],[@B17-pathogens-02-00556]\].

As the databases created from relatively open-ended culture-independent methods, such as high-throughput sequencing, expand, the opportunity to effectively apply closed methods expands. Given a sufficiently large database developed through the systemic application of an open method, such as sequencing, these closed methods have the potential to reveal the full diversity of microbes present in a sample, despite the theoretical limitation on the ability to detect or characterize a "never seen before" organism. Quantitative PCR \[[@B18-pathogens-02-00556],[@B19-pathogens-02-00556]\], Nanostring \[[@B20-pathogens-02-00556]\] or microarray hybridization \[[@B21-pathogens-02-00556],[@B22-pathogens-02-00556]\] and multiplex fluorescence *in situ* hybridization (FISH) \[[@B23-pathogens-02-00556]\] provide the ability to quantify taxa through their nucleic acid signatures and may be directly applied to samples (not isolates) to quantify an immense diversity of uncultured microbes directly from clinical samples without isolation. MALDI-TOF MS sensitively and specifically detects the ribosomal proteins; it has been applied to blood bottles \[[@B24-pathogens-02-00556],[@B25-pathogens-02-00556]\]---culture without isolation---and may eventually be used directly on selected clinical samples \[[@B26-pathogens-02-00556]\]. Compared to sequencing, these closed methods each have advantages on the basis of cost, simplicity, sensitivity or speed.

1.2. The Clinical Relevance of Microbial Diversity
--------------------------------------------------

The clinical importance of the previously unaccounted microbial diversity will be inevitably recognized. Current practice is most precise when one of a few clearly identified, readily cultivated pathogens cause a clearly delineated clinical presentation. In such cases, selective culture is a sensitive strategy for diagnostic confirmation, epidemiology and, possibly, environmental surveillance. In other clinical scenarios, the art of the microbiologist is sufficient to render a sophisticated interpretation of circumstantial laboratory evidence to the clinician supporting the current standard of care; this practical experience enables empiric therapy by formally and informally incorporating local and communal outcome data \[[@B27-pathogens-02-00556],[@B28-pathogens-02-00556]\]. However, at the margins of clinical practice are uncultivable infections (such as orthopedic infections \[[@B29-pathogens-02-00556]\], otitis media \[[@B30-pathogens-02-00556]\] and brain abscesses \[[@B31-pathogens-02-00556],[@B32-pathogens-02-00556]\]), obviously polymicrobial infections (such as chronic ulcers and oral infections \[[@B33-pathogens-02-00556]\]) and diseases of unknown cause (including intestinal inflammatory diseases). In each of these cases, arguments made about detecting extra-cellular DNA, non-viable organisms \[[@B34-pathogens-02-00556]\], "contaminants" \[[@B35-pathogens-02-00556]\] and "irrelevant" normal flora \[[@B36-pathogens-02-00556]\] are overcome by new data. Given the relevance of previously undetected flora to the clinical status of the patient, it is logically deduced that clinically practical culture methods do not provide accurate diagnostic data in these cases.

Unfortunately, even when clinical culture misses a relevant fraction of the diversity and poorly enumerates the culturable organisms, the data is accepted uncritically, because of historical precedent, overwhelming volume and apparent internal consistency. The minority voice, suggesting that this data does not represent the whole picture, barely registers. There is no vibrant, antagonistic debate between those who understand and practice sophisticated culture-based microbiology and those who would advocate culture-independent microbiology; instead, there is a failure to communicate between those who understand both and those who have not thought deeply about either. The leading clinical microbiologists are themselves the most engaged in the efforts to redefine clinical practice, finding appropriate limits for the use of culture. To quote George Bernard Shaw, "Those who understand the steam engine and the electric telegraph spend their lives in trying to replace them with something better \[[@B37-pathogens-02-00556]\]."

2. The Example of Wound Infections
==================================

As an example of the difficulties caused by culture methods as presently applied, full-fledged hospital epidemiology studies of infections compare infection rates under different treatment conditions and attempt to relate the environmental presence of the relevant pathogens to the pathogens recovered from patients \[[@B38-pathogens-02-00556],[@B39-pathogens-02-00556],[@B40-pathogens-02-00556],[@B41-pathogens-02-00556],[@B42-pathogens-02-00556]\]. For a wound infection study, the supporting data is composed of three parts: wound infection rates, the identity of the bacteria isolated from the wounds and the identity and quantity of bacteria from environmental surveillance. Conceptually, these three data sets are sufficient to correlate bacteria in the hospital environment with the same bacteria causing wound infections in patients. However, the use of culture compromises the data.

2.1. Infection Rates
--------------------

Current guides to diagnosing surgical site and soft-tissue wound infections (wound assessment) still rely on the color of the wound bed, wound odor and exudate quantity/viscosity \[[@B43-pathogens-02-00556],[@B44-pathogens-02-00556],[@B45-pathogens-02-00556],[@B46-pathogens-02-00556]\]. The most modern alternate is a subjective assessment of pain trends by the patient \[[@B47-pathogens-02-00556]\]. Subjective observations are almost self-evidently inadequate as diagnostic tools \[[@B48-pathogens-02-00556],[@B49-pathogens-02-00556],[@B50-pathogens-02-00556]\]; however, the alternative, clinical microbiology, is unable to distinguish infection from colonization or contamination of the wound, and experienced wound care practitioners routinely ignore culture results, if they request them in the first place \[[@B51-pathogens-02-00556],[@B52-pathogens-02-00556]\].

2.2. The Identity of the Isolates from the Wounds
-------------------------------------------------

Clinical results reported in the literature are also unlikely to consistently identify and characterize "the wound pathogen". Clinical microbiology for wound infections is typically a Gram stain and culture. The Gram stains and cultures typically are discordant when compared critically \[[@B53-pathogens-02-00556]\]. Submitted samples from physicians are usually swabs (recommendations from: Wounds UK, "Identifying Infection: Taking a Swab" \[[@B54-pathogens-02-00556]\]; and recent publications \[[@B55-pathogens-02-00556],[@B56-pathogens-02-00556],[@B57-pathogens-02-00556],[@B58-pathogens-02-00556]\]). This sampling strategy is flawed \[[@B59-pathogens-02-00556],[@B60-pathogens-02-00556],[@B61-pathogens-02-00556]\], but remedying this is a low priority, because the downstream culture process is also ineffective.

The clinical microbiologist typically selects a "representative" colony from the initial isolation, one not judged to be a "contaminant" or "commensal" by gross inspection of the Petri plate, and performs biochemical identification and antibiotic susceptibility tests. This down-selection to a single colony suppresses all interspecific and intraspecific diversity; also, various organisms previously considered to be "contaminants" are now known to have a role in infection \[[@B62-pathogens-02-00556],[@B63-pathogens-02-00556],[@B64-pathogens-02-00556],[@B65-pathogens-02-00556],[@B66-pathogens-02-00556],[@B67-pathogens-02-00556],[@B68-pathogens-02-00556],[@B69-pathogens-02-00556],[@B70-pathogens-02-00556],[@B71-pathogens-02-00556],[@B72-pathogens-02-00556],[@B73-pathogens-02-00556],[@B74-pathogens-02-00556]\]. In addition, contributing pathogens may not even grow on the plate; those that do may acquire specific "domestication" adaptations in the laboratory. Many wound organisms are functionally uncultured (slow to grow species, viable non-culturable, strict anaerobes, microaerophiles, requiring co-culture, *etc*.) \[[@B16-pathogens-02-00556],[@B61-pathogens-02-00556],[@B75-pathogens-02-00556],[@B76-pathogens-02-00556],[@B77-pathogens-02-00556],[@B78-pathogens-02-00556]\]. The cultured organisms may not be numerous organisms \[[@B17-pathogens-02-00556]\]; and abundance may not always be an indication of relative pathogenic impact \[[@B79-pathogens-02-00556]\]. Whether the isolates are ultimately characterized biochemically or molecularly, relevant organisms are excluded by virtue of isolate collection.

The final step of clinical microbiology is antibiotic susceptibility testing. However, in many cases, *in vitro* antibiotic susceptibility does not match *in vivo* clinical response to the antibiotics \[[@B80-pathogens-02-00556]\]. While there are some mechanistic reasons for this (biofilm formation, domestication adaptations, pharmacokinetics/pharmacodynamic variation, persisters, *etc*.), one overlooked issue is the probability that the primary pathogens were not the organisms tested for susceptibility. Ongoing debate in the wound care field challenges the clinical importance of the full microbial diversity, but recently, a clinical trial appears conclusive \[[@B76-pathogens-02-00556]\]. Recent results have not yet had their ultimate impact on the medical arts: treating infected wounds based on identification of all the organisms, culturable or not, enables wound healing in cases where amputation was judged largely inevitable.

2.3. The Identity and Quantity of Bacteria from Environmental Surveillance
--------------------------------------------------------------------------

The difficulty of environmental microbial sampling is well known by environmental microbiologists; culture-based microbiological surveys have, since the times of Beijerinck (1901) and Winogradsky (1890), been recognized as insufficient to study environmental microbial populations. However, they continue to be used by epidemiology and infection control programs \[[@B38-pathogens-02-00556],[@B81-pathogens-02-00556],[@B82-pathogens-02-00556],[@B83-pathogens-02-00556],[@B84-pathogens-02-00556]\], in large part due to a conviction that "medically relevant pathogens" are well-known and easily cultured. The current practices of pathogen surveillance mimic practices in clinical microbiology. Frequently, the methods are scrupulously imported from the clinical laboratory to surveillance; and the laboratory facilities, perhaps even the personnel, are shared. As in diagnostics, it is expensive and impractical to isolate all the colonies from a plate, colony morphology is used as a proxy for identity, "relevant" organisms are preferentially retained and culture is that obsidian lens through which all microbial diversity is filtered. Even molecular (PCR, pulse field gel electrophoresis (PFGE), sequencing) studies of "well-characterized" nosocomial pathogens \[[@B85-pathogens-02-00556],[@B86-pathogens-02-00556],[@B87-pathogens-02-00556],[@B88-pathogens-02-00556]\] fundamentally rely on collection of isolates; while the relationships among isolates themselves may be well-understood, the underlying frequency and distribution data is untrustworthy.

In short, mutually reinforcing confirmation bias between clinical isolate statistics and surveillance statistics limits self-correction. The microbiological aspect of hospital epidemiology for wound infections is built on ineffective characterization of random subsamples from non-representative samples; when reading the literature, one can trust neither wound infection rate nor wound pathogen identification statistics (e.g., Guggenheim *et al*. 2009) \[[@B89-pathogens-02-00556]\]. The misrepresentation of pathogens is now known to occur in numerous clinical presentations \[[@B90-pathogens-02-00556],[@B91-pathogens-02-00556],[@B92-pathogens-02-00556],[@B93-pathogens-02-00556],[@B94-pathogens-02-00556],[@B95-pathogens-02-00556],[@B96-pathogens-02-00556]\]. It has been long recognized that the quality of the underlying data with regard to acute respiratory disease created a fetid myiasis of misinformation when compounded uncritically \[[@B97-pathogens-02-00556]\].

3. Hope and Change
==================

Eventually, the expanded scientific literature will correct our misunderstandings of the microbial world; but presently, the cumulative culture-independent data are dwarfed by on-going culture-based pathogen surveillance. Volumes of historical data assert their relevance through mere existence. In addition, the continued use of culture is locked-in by the integration of culture-dependent diagnostics and the current generations of antibiotics. If a clinical condition (e.g., the presence of an uncultured organism in the context of certain signs and symptoms) is detectable only with culture-independent methods, specific therapeutics will not be developed until the diagnostics are deployed widely enough to stimulate demand. Meanwhile, culture-independent methods will not be deployed widely unless the data they generate can be used to select specific therapeutics---otherwise, it appears the money is wasted, because clinical decisions are unchanged. Antimicrobial development is lengthy \[[@B98-pathogens-02-00556],[@B99-pathogens-02-00556]\] and the advance of sophisticated diagnostics too far ahead of therapeutics, presenting the specter of clinicians stoic in the face of infections understood, yet untreatable.

Fortunately, there are a number of on-going initiatives that will smooth the way forward towards a broadened view of infectious disease, including an appropriate interpretation of historical culture-biased data. Historically, culture-independent methods were costly, technically challenging, difficult to decipher and hard to compare across studies. The infectious disease community is well aware of the rapidly decreasing cost of producing culture-independent data \[[@B100-pathogens-02-00556]\]; it is perhaps increasingly aware of the vendors willing to perform microbial sequencing on raw samples (Second Genome, Inc., San Bruno, CA, USA; Mr. DNA, Research and Testing, Inc., Lubbock, TX, USA; and other certified service laboratories). Complementing the accessibility of data, high quality analysis is becoming manageable as the scientific community creates workflow management systems, pipelines and integrated packages. General purpose workflow management systems (Taverna \[[@B101-pathogens-02-00556]\], Galaxy \[[@B102-pathogens-02-00556]\], *etc*.) are available both for local installation and as web services. Integrated packages, such as MG-Rast \[[@B103-pathogens-02-00556]\], Qiime \[[@B104-pathogens-02-00556]\], AXIOME \[[@B105-pathogens-02-00556]\] and mothur \[[@B106-pathogens-02-00556]\], provide pre-defined and customizable, validated, published strategies for analyzing complex metagenome or community 16S rRNA data. While there is no substitute for an understanding of microbiology and molecular biology, these packages reduce the burden of the bioinformatics knowledge required to enter the field. In addition, several of these packages \[[@B107-pathogens-02-00556],[@B108-pathogens-02-00556],[@B109-pathogens-02-00556]\] are pre-configured to run on commercial computer systems (IaaS/PaaS or "cloud" computing), such as Amazon Web Services, so that the user does not need to have a significant investment in computing hardware and infrastructure, but is able to obtain highly responsive, timely results at a scalable cost. Costs for this strategy have been analyzed and published \[[@B110-pathogens-02-00556]\]. Finally, several tools are integrated with open data archives or platforms for sharing data in various stages of analysis (MG-Rast \[[@B103-pathogens-02-00556]\], HMP DACC \[[@B111-pathogens-02-00556],[@B112-pathogens-02-00556]\], MoBeDAC, IMG \[[@B113-pathogens-02-00556]\]). This builds on the model of GenBank, which set a gold standard for data availability in the earlier years of sequencing. Open and easily accessible archives allow for integrated analyses, comparative studies, methods validation and re-analysis as new questions arise; and they are populated more quickly than data is published, in many cases, allowing for studies to build on each other ever more rapidly, with appropriate attribution.

Open data is a great innovation; open publication is also common in this particular research community. This has sped the availability of baseline data for the microbiome of humans, animals and the built environment. On-going projects and programs are producing baseline data for important collection sites, including every site on the human, in the home and throughout the hospital. The more rapid this accumulation of data and the more clinical and surveillance culture-independent data is available, the more meaningful new data becomes.

4. Conclusions
==============

Eventually, it should be possible to rehabilitate the culture-dependent literature, given an understanding of how the culturable fraction of microbes participates in and represents the larger microbial population from which it was drawn. Understanding weaknesses and confounders is critical to successfully utilizing the strengths of that literature. On the way to this vision, it is necessary to describe that larger microbial population and tie it to accurate diagnostic data, attentive to all the organisms in the patient or environment. In the process of collecting samples from environmental and clinical samples, molecular data is required to identify both the background assemblage of microbes in the sample, as well as to raise awareness of any additional strains of the same species, which are potentially important in epidemiology and pathogenesis \[[@B114-pathogens-02-00556],[@B115-pathogens-02-00556]\], but may not be represented in culture or are a minority population not detected when single colonies are collected.

In the interim, however, it is almost impossible to restrain the wealth of misinformation. Many readers, including administrators, policy makers and clinicians, are not afforded the time or subject matter expertise required to delve into the methods of each paper or report; they will not understand the issues inherent in conclusions presented, particularly when those conclusions concord with what was taught in schools, publicized in the press and was historically acceptable. "The difficulty lies, not in the new ideas, but in escaping from the old ones, which ramify, for those brought up as most of us have been, into every corner of our minds \[[@B116-pathogens-02-00556]\]."

In this case, the continuing flood of culture-biased data may slow progress towards enhanced medical care. Conscious efforts on the part of journal editors and subject matter experts are required to emphasize the limitations of data based on cultured isolate statistics and to encourage the inclusion of the culture-independent context whenever isolate data must be used for epidemiology, public health or infectious disease publication.
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